Itonis Inc (ITNS)

[profiteer11]

Quarterly out today
"B. Describe the issuers’ principal products or services.
In 2012, the Company launched a new Itonis Pharmaceuticals division to produce and market over the counter
and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company
has launched the retails sale of the Emesyl® nausea relief product. The Company has identified the market for
its Emesyl® product line as the general public who suffers from nausea. Emesyl® has been available for
purchase at https://www.amazon.com/dp/B00U20H3KI and www.Emesyl.com.
In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl®
product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS
distribution centers in Texas. We had expected to gather feedback with performance metrics via an online
dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it
being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an
action plan will be developed by the CVS category manager to expand distribution to more of their stores, which
is typically executed in their next CVS planogram cycle. We will see what the Test & Learn Program will tell us.
Meanwhile, the Company’s Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl®
nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor.
The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line
within its wholly-owned subsidiary, Itonis Holdings, Inc.
On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in
exchange for 147,000,000 shares of Smart Cannabis, Inc’s common stock."

Smart Cannabis Corp. (SCNA)